Characteristics of Hgb C Carriers in Northern Israel and Clinical Features Among Hgb Homozygous - Full Text View

Sponsored by:	HaEmek Medical Center, Israel
Information provided by:	HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:	NCT00481260

Purpose

Hgb C is an hemoglobinopathy quite rare in Israel. The clinical status of patients that are diagnosed as homozygous to this disease is quite benign but not study in large groups.

Also the characteristics of carriers and the incidence in northern Israel were a large arab population lives, was not study. The results of this study can be useful for screening purpose in a area were another hemoglobinopathies are frequent.

Condition	Intervention
Hgb C Hemoglobinopathy	Procedure: Medical history and basic laboratory analysis

U.S. FDA Resources

Study Type:	Observational
Study Design:	Natural History, Cross-Sectional, Defined Population, Retrospective Study
Official Title:	Characteristics of Hgb C Carriers in Northern Israel and Clinical Features Among Hgb Homozygous

Further study details as provided by HaEmek Medical Center, Israel:

Estimated Enrollment:	100
Study Start Date:	May 2007
Estimated Study Completion Date:	December 2007

Detailed Description:

Hgb C is an hemoglobinopathy quite rare in Israel. The clinical status of patients that are diagnosed as homozygous to this disease is quite benign but not study in large groups.

Also the characteristics of carriers and the incidence in northern Israel were a large arab population lives, was not study. The results of this study can be useful for screening purpose in a area were another hemoglobinopathies are frequent.

The study will record the clinical characteristics of the homozygous Hgb C patients and the hematology characteristics of all the heterozygous carriers detected in northern Israel

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

All patients diagnosed as homozygous for Hgb C disease or double heterozygous in combination to other abnormal hemoglobin, and all the carriers detected in the hematology laboratory during the screening for abnormal hemoglobins in northern Israel

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00481260

Contacts

Contact: Ariel Koren, MD

972-4-6495576 ext 5576

koren_a@clalit.org.il

Locations

Israel
Pediatric Hematology Unit - HaEmek Medical Center
Afula, Israel, 18101

Sponsors and Collaborators

HaEmek Medical Center, Israel

Investigators

Study Director:	Ariel Koren, MD	Pediatric Hematology Unit, Ha'Emek Medical Center
Study Chair:	luci Zalman, Phd	Hematology Laboratory - HaeEmek Medical Center

More Information

Study ID Numbers:	5100706.EMC
Study First Received:	May 31, 2007
Last Updated:	May 31, 2007
ClinicalTrials.gov Identifier:	NCT00481260
Health Authority:	Israel: Ministry of Health

Keywords provided by HaEmek Medical Center, Israel:

Hgb C
Screening

Study placed in the following topic categories:

Genetic Diseases, Inborn
Hematologic Diseases
Hemoglobinopathies
Hemoglobinopathy

ClinicalTrials.gov processed this record on January 16, 2009